日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Efficacy and safety of bofanglutide, a GLP-1 receptor agonist, in Chinese adults with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trial

一项随机、双盲、安慰剂对照的2b期临床试验,旨在评估GLP-1受体激动剂波方鲁肽在中国超重或肥胖成年人中的疗效和安全性。

Ji, Linong; Gao, Leili; Tian, Junhang; Dong, Ruihua; Zhang, Zhongtao; Shu, Hongyan; Zhao, Jing; Zhao, Liyuan; He, Anshun; Xie, Tian; Li, Yue; Chen, Wei

Oral Semaglutide and Change in Cardiovascular Risk Factors in High-Risk Type 2 Diabetes: A Post Hoc Secondary Analysis of the SOUL Randomized Clinical Trial

口服索马鲁肽对高危 2 型糖尿病患者心血管危险因素的影响:SOUL 随机临床试验的事后二次分析

Mulvagh, Sharon L; Inzucchi, Silvio E; Marx, Nikolaus; Poulter, Neil R; Deanfield, John E; Pop-Busui, Rodica; Emerson, Scott S; Mann, Johannes F E; Engelmann, Mads D M; Hovingh, G Kees; Mandavya, Kabirdev; Davicevic-Elez, Zaklina; Jeppesen, Ole Kleist; Lorenzatti, Alberto; Oguz, Aytekin; Mankovsky, Boris; Deerochanawong, Chaicharn; Gorgojo-Martinez, Juan J; Ji, Linong; Bain, Stephen C; McGuire, Darren K; Buse, John B

GZR18, a GLP-1 analog with once-weekly or bi-weekly dosing for body weight management: A randomized, placebo-controlled, phase 1b/2a trial

GZR18,一种用于体重管理的GLP-1类似物,每周一次或每两周给药一次:一项随机、安慰剂对照的1b/2a期试验

Ji, Linong; Gao, Leili; Dong, Ruihua; Yuan, Mingxia; Zhao, Dong; Pang, Shuguang; Zhao, Jing; Zhao, Liyuan; Chen, Wei

From global guidelines for cardio-kidney-metabolic diseases management to national implementation: perspectives from the guideline workshop taskforce

从全球心肾代谢疾病管理指南到国家实施:指南研讨会工作组的视角

Wanner, Christoph; Cosentino, Francesco; Barnard-Kelly, Katharine; Battelino, Tadej; Blüher, Matthias; Boll, Helena N; Brosius, Frank C; Busetto, Luca; Ceriello, Antonio; Gavin, James R 3rd; Giorgino, Francesco; Green, Jennifer; Ji, Linong; Kellerer, Monika; Koob, Sue; Lalic, Nebojsa; Marx, Nikolaus; Nedungadi, Prashant; Parkin, Christopher G; Rodbard, Helena W; Rydén, Lars; Saboo, Banshi; Sheu, Wayne Huey-Herng; Standl, Eberhard; Tacke, Frank; Topsever, Pinar; Schnell, Oliver

Correction: Trajectory of the body weight after drug discontinuation in the treatment of anti-obesity medications

更正:抗肥胖药物治疗停药后体重的变化轨迹

Wu, Han; Yang, Wenjia; Guo, Tong; Cai, Xiaoling; Ji, Linong

Addressing unmet needs for chronic kidney disease treatment in type 1 diabetes: A review

解决1型糖尿病合并慢性肾脏病治疗中未满足的需求:一项综述

Tuttle, Katherine R; Ji, Linong; Mathieu, Chantal; Rosen, Jonathan

CGM-derived efficacy and overall safety of once-weekly insulin efsitora alfa (efsitora) relative to day of administration in adults with type 2 diabetes

在2型糖尿病成人患者中,每周一次注射胰岛素efsitora alfa(efsitora)的CGM衍生疗效和总体安全性与给药当日相比

Martens, Thomas; Battelino, Tadej; Heller, Simon; Bhargava, Anuj; Ji, Linong; Murthy, Sreenivasa; Threlkeld, Rebecca J; Li, Xiaoqi; Murro, Ada Leticia; Syring, Kristen; Patel, Vidhi

Factors Affecting the Treatment Heterogeneity of PPARγ and Pan-PPAR Agonists in Type 2 Diabetes Mellitus: A Systematic Review and Machine Learning-Based Meta-Regression Analysis

影响2型糖尿病中PPARγ和泛PPAR激动剂治疗异质性的因素:系统评价和基于机器学习的Meta回归分析

Zhang, Xinlei; Liu, Yingning; Chu, Ming; Ji, Linong; Zou, Xiantong

Case Report: Abnormally low hemoglobin A1c in a diabetic patient with SLC4A1 gene mutation

病例报告:SLC4A1基因突变糖尿病患者糖化血红蛋白A1c异常偏低

Ye, Lili; Ren, Qian; Ba, Tianhao; Wu, Jing; Han, Xueyao; Ji, Linong

Redefining evidence for teprotumumab in thyroid eye disease: an updated meta-analysis of efficacy and safety

重新定义替普鲁单抗治疗甲状腺眼病的证据:一项更新的疗效和安全性荟萃分析

Song, Rongjing; Zhao, Wei; Li, Shasha; Niu, Xiaofang; Guo, Jing; Zhang, Xiuying; Zhang, Xiaohong; Ji, Linong